Hold-rated reports

904 tickers rated Hold
NewestHighest Score Ranks all reports in this rating group by score, highest first.
Brookfield Renewable Corporation
BEPC·Utilities
B ★★★Hold
Current$31.74
Target$36.00
Return+13.4%
Nov 7, 2026

Brookfield Renewable offers contracted renewable power cash flows, an attractive dividend, and restructuring upside, but high leverage and capital-intensive growth constrain its margin of safety.

Score
67
ESAB Corporation
ESAB·Industrials
B ★★★Hold
Current$82.83
Target$90.00
Return+8.7%
Nov 7, 2026

ESAB combines a durable global welding franchise with expanding inspection capabilities, but elevated acquisition leverage and modest organic growth make cash-flow recovery essential to unlocking shareholder value.

Score
67
Blackstone Secured Lending Fund
BXSL·Financials
B ★★★Hold
Current$24.09
Target$24.49
Return+1.7%
Nov 7, 2026

Blackstone Secured Lending Fund offers substantial income backed by a predominantly first-lien private-credit portfolio and institutional lending expertise, but weakening earnings, rising non-accrual loans, and NAV erosion constrain its upside.

Score
67
Coherent Corp.
COHR·Technology
B ★★★Hold
Current$192.81
Target$251.46
Return+30.4%
Nov 7, 2026

Coherent's advanced optical networking technology positions it for sustained AI infrastructure growth, but heavy capital spending, negative free cash flow, and shareholder dilution threaten the conversion of that growth into lasting per-share value.

Score
67
Enact Holdings, Inc.
ACT·Financials
B ★★★Hold
Current$46.43
Target$47.98
Return+3.3%
Nov 7, 2026

Enact generates strong insurance profits and substantial shareholder returns through a well-capitalized mortgage insurance franchise, but its valuation premium and rising credit losses limit near-term upside.

Score
67
Brookfield Renewable Partners L.P.
BEP·Utilities
B ★★★Hold
Current$31.14
Target$34.45
Return+10.6%
Nov 7, 2026

Brookfield Renewable combines contracted renewable-power cash flows, growing FFO and attractive distributions, but high leverage, capital-intensive expansion and execution risk constrain its valuation upside.

Score
67
Solaris Energy Infrastructure, Inc.
SEI·Energy
B ★★★Hold
Current$57.77
Target$74.40
Return+28.8%
Nov 7, 2026

Solaris offers substantial upside from long-duration data-center power contracts and rapid earnings growth, but heavy capital spending, leverage and deployment risk could prevent that growth from translating into shareholder cash returns.

Score
67
Chunghwa Telecom Co., Ltd.
CHT·Communication Services
B ★★★Hold
Current$49.85
Target$44.20
Return-11.3%
Nov 7, 2026

Chunghwa Telecom offers a dominant Taiwanese network franchise, dependable cash generation, and recurring dividends, but its elevated valuation leaves limited upside unless enterprise ICT growth materially improves sustainable earnings.

Score
67
Essential Utilities, Inc.
WTRG·Utilities
B ★★★Hold
Current$46.05
Target$47.60
Return+3.4%
Nov 6, 2026

Essential Utilities offers durable regulated infrastructure earnings, an established dividend record, and potential merger benefits, but heavy capital spending, leverage, and American Water transaction risk constrain upside.

Score
67
British American Tobacco p.l.c.
BTI·Consumer Staples
B ★★★Hold
Current$63.08
Target$67.60
Return+7.2%
Nov 6, 2026

British American Tobacco combines durable nicotine cash flows, an attractive dividend and growing smokeless products, but structural cigarette decline, regulatory exposure and an elevated historical valuation limit upside.

Score
67
PJT Partners Inc.
PJT·Financials
B ★★★Hold
Current$153.48
Target$163.21
Return+6.3%
Nov 6, 2026

PJT Partners combines a high-return independent advisory franchise with long-term growth opportunities in restructuring and private capital, but cyclical deal fees and a demanding historical valuation constrain near-term upside.

Score
67
Koninklijke Philips N.V.
PHG·Healthcare
B ★★★Hold
Current$30.51
Target$34.08
Return+11.7%
Nov 6, 2026

Philips offers exposure to improving medical technology demand and a credible margin recovery at a reasonable normalized valuation, but Respironics liabilities and modest returns on capital constrain its rerating potential.

Score
67